Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) and Vaccinex (NASDAQ:VCNX – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
This is a breakdown of recent ratings and target prices for Ascendis Pharma A/S and Vaccinex, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ascendis Pharma A/S||0||1||10||0||2.91|
Ascendis Pharma A/S presently has a consensus target price of $163.40, suggesting a potential upside of 72.16%. Given Ascendis Pharma A/S’s higher probable upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Vaccinex.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ascendis Pharma A/S||$9.20 million||587.65||-$453.81 million||($9.36)||-10.14|
Vaccinex has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Ascendis Pharma A/S has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
Insider & Institutional Ownership
48.6% of Vaccinex shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 47.6% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Ascendis Pharma A/S and Vaccinex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ascendis Pharma A/S||-3,281.45%||-54.58%||-39.31%|
Vaccinex beats Ascendis Pharma A/S on 7 of the 13 factors compared between the two stocks.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.